Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Negative operating cash flowResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹81.50

prior close

₹80.81

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-7.2% vs market

Pharmaceuticals peers, median of 160sector+0.2%-6.3% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.5

10m

-3.5

15m

-4.3

30m

-4.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1+1.1-7.2+0.2-6.3

Next day

-6.2+1.2-7.4+0.2-6.4

-6.3+2.8-9.1+1.5-7.8

-6.1+3.5-9.7+1.4-7.6

-6.1+3.5-9.6+1.6-7.7

-6.1+2.8-9.0+1.0-7.2

-7.5+2.8-10.3+0.4-7.9

15d

-2.5+4.2-6.7+0.7-3.2

-3.2+10.1-13.3+3.1-6.3

-1.4+10.0-11.4+7.2-8.6

-6.3+14.6-20.8+8.2-14.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma reported FY2026 revenue of Rs. 77,166 Lakhs, up 16.6% from Rs. 66,151 Lakhs in FY2025, driven by higher volumes in bulk drugs and chemicals. However, profit after tax declined 13.3% to Rs. 4,105 Lakhs from Rs. 4,735 Lakhs, impacted by rising raw material costs and unfavorable forex movements. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The company declared a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval. A 1:1 bonus issue was completed in July 2025, doubling the equity share capital to Rs. 5,011 Lakhs. The audit opinion remains unmodified with no qualifications. Nine promoter group shareholders (holding 0.95% stake) have sought reclassification to public category.

Likely market impact

Revenue growth of 16.6% shows solid business expansion, but the 13.3% PAT decline and EBITDA margin compression of over 2 percentage points signal cost pressures that may concern investors. The clean audit and dividend declaration provide some support. The promoter reclassification request is minor at under 1% stake.

By the numbersStandalone · Q4 FY26 vs Q4 FY25

	Q4 FY26	Q4 FY25	Change
Revenue	₹202.1 Cr	₹198.1 Cr	+2.0%
Operating profit	₹16.77 Cr	₹15.88 Cr	+5.6%
Profit after tax	₹11.68 Cr	₹12.46 Cr	−6.2%
EBITDA margin	9.8%	9.4%	+0.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.